Skip to main content

Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens (Grand Rounds)


Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Friday, December 2, 2022
4:00 - 5:00 PM ET (3:00 - 4:00 PM CT / 1:00 - 2:00 PM PT)

Wednesday, December 14, 2022
12:00 - 1:00 PM MT (2:00 - 3:00 PM ET / 11:00 - 12:00 PM PT)


  • Welcome and Introductions
  • Guideline-based Management of Metastatic Pancreatic Cancer
  • Emerging Testing and Treatment Approaches for Metastatic Pancreatic Cancer
  • Q&A Session and Activity Roundup

Metastatic pancreatic cancer is a serious malignancy with limited treatment options and poor outcomes. It is also growing in incidence, and it is projected to be the second leading cause of cancer-related death before 2030. Treatment of pancreatic cancer relies primarily on chemotherapy, though targeted therapies are now available for the approximately 20% of patients who express actionable genetic alterations. Additionally, novel targeted therapies and immunotherapies are showing promise in early phase clinical trials, providing potential future treatment options for this deadly malignancy.

Selection between currently available treatment options and ongoing clinical trials relies heavily on biomarkers, as well as performance status, comorbidities, and patient preference. Communicating with patients regarding the importance of biomarker testing, treatment selection, and clinical trials is key to ensuring the best outcomes for patients with metastatic pancreatic cancer.

This activity, Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens, will provide oncology clinicians with information on the most recent biomarkers and treatments for metastatic pancreatic cancer, expert recommendations for treatment selection and sequencing, and updated information on emerging biomarkers and targeted therapies for pancreatic cancer.

   Michael J. Pishvaian, MD, PhD
te Professor, Department of Oncology
   Johns Hopkins University School of Medicine
   Washington, DC

Rachna Shroff, MD, MS
Interim Chief, Division of Hematology/Oncology
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Associate Dean, Clinical and Translational Research, UA-COM
Associate Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA-COM)
Tucson, AZ


The intended audience for this educational initiative is oncologists and other clinicians who manage patients with metastatic pancreatic cancer.

At the conclusion of this activity, participants should be able to:
  • Evaluate patients with metastatic pancreatic cancer based on current guideline recommendations for imaging and testing
  • Select evidence-based treatments for patients with metastatic pancreatic cancer accounting for patient performance, comorbidities, and preferences
  • Effectively communicate with patients with metastatic pancreatic cancer regarding genetic testing, treatment goals and preferences, and clinical trials
  • Discuss the prognostic and predictive potentials of emerging genetic tests to inform treatment selection for patients with pancreatic cancer
  • Evaluate the safety and efficacy of emerging therapies for metastatic pancreatic cancer

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.

PCME Privacy Policy